E
Edward A. Kesicki
Researcher at Eli Lilly and Company
Publications - 26
Citations - 901
Edward A. Kesicki is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Protein kinase A & DNA damage. The author has an hindex of 11, co-authored 25 publications receiving 891 citations. Previous affiliations of Edward A. Kesicki include Albany Molecular Research, Inc..
Papers
More filters
Patent
Inhibitors of human phosphatidyl-inositol 3-kinase delta
Chanchal Sadhu,Kenneth O. Dick,Jennifer Treiberg,C. Gregory Sowell,Edward A. Kesicki,Amy Oliver +5 more
TL;DR: In this article, methods of inhibiting PI3K delta isoform (PI3Kδ) activity, and methods of treating diseases such as disorders of immunity and inflammation in which PI3kδ plays a role in leukocyte function, using the compounds also are disclosed.
Journal ArticleDOI
DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs
Eric T. Shinohara,Ling Geng,J. Tan,Heidi Chen,Yu Shir,Eric Edwards,James Halbrook,Edward A. Kesicki,Adam Kashishian,Dennis E. Hallahan +9 more
TL;DR: Radiosensitization by IC87361 was eliminated in SCID tumor vasculature, which lack functional DNA-PK, an important target for the development of novel radiation-sensitizing drugs that have little intrinsic cytotoxicity.
Journal Article
DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer
Adam Kashishian,Heather Douangpanya,Darcey Clark,Stephen T. Schlachter,C. Todd Eary,Justin G. Schiro,Hongmei Huang,Larry E Burgess,Edward A. Kesicki,James Halbrook +9 more
TL;DR: These studies validate DNA-PK as a cancer drug target and suggest a new approach for enhancing the effects of existing cancer therapies, which synergistically enhances radiation-induced tumor control in a mouse-human xenograft assay.
Patent
Compounds useful for inhibiting Chk1
Kathleen S. Keegan,Edward A. Kesicki,John Gaudino,Cook Adam,Cowen Scott Douglas,Laurence E. Burgess +5 more
TL;DR: Aryl and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed in this paper.
Journal ArticleDOI
A Specific Antagonist of the p110δ Catalytic Component of Phosphatidylinositol 3′-Kinase, IC486068, Enhances Radiation-Induced Tumor Vascular Destruction
Ling Geng,Jiahuai Tan,Eric Himmelfarb,Aaron J. Schueneman,Ken Niermann,Allie Fu,Kyle C. Cuneo,Edward A. Kesicki,Jennifer Treiberg,Joel S. Hayflick,Dennis E. Hallahan +10 more
TL;DR: The effects of the p110δ specific inhibitor IC486068, which abrogated radiation-induced phosphorylation of Akt, suggest that p 110δ is a therapeutic target to enhance radiation- induced tumor control.